Dexmedetomidine Neuroprotection in Pediatric Cardiac Surgery

• Status: Recruiting
• Trial end date: 2023-05-31
• Target enrollment: 0
• Participant gender: All

Summary

Neurodevelopmental disability is the most significant complication for survivors of infant surgery for congenital heart disease. In this study we sought to determine if intraoperative continuous infusion of dexmedetomidine are associated with neurodevelopmental outcomes at 12 months.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Neonates undergoing cardiac surgery

• Infants undergoing cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

• STAT category 4,5

• staged operation (BT shunt, BCPS)

• surgery with deep hypothermic circulatory arrest

• aspartate transaminase >100unit/L, alanine aminostrasferase > 100 unit/L